Review



sigmoidal dose-response algorithm (as implemented in graphpad prism 7)  (GraphPad Software Inc)


Bioz Verified Symbol GraphPad Software Inc is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    GraphPad Software Inc sigmoidal dose-response algorithm (as implemented in graphpad prism 7)
    TNBC and non-TNBC cell cisplatin IC 50 values in the presence and absence of the BAD pathway kinase inhibitors perifosine and H89. Drug IC 50 values were computed using GraphPad with Sigmoidal <t> dose-response algorithm. </t>
    Sigmoidal Dose Response Algorithm (As Implemented In Graphpad Prism 7), supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sigmoidal+dose-response+algorithm+%28as+implemented+in+graphpad+prism+7%29/pmc06877530-209-20-25?v=GraphPad+Software+Inc
    Average 90 stars, based on 1 article reviews
    sigmoidal dose-response algorithm (as implemented in graphpad prism 7) - by Bioz Stars, 2026-07
    90/100 stars

    Images

    1) Product Images from "Expression of the BAD pathway is a marker of triple-negative status and poor outcome"

    Article Title: Expression of the BAD pathway is a marker of triple-negative status and poor outcome

    Journal: Scientific Reports

    doi: 10.1038/s41598-019-53695-0

    TNBC and non-TNBC cell cisplatin IC 50 values in the presence and absence of the BAD pathway kinase inhibitors perifosine and H89. Drug IC 50 values were computed using GraphPad with Sigmoidal dose-response algorithm.
    Figure Legend Snippet: TNBC and non-TNBC cell cisplatin IC 50 values in the presence and absence of the BAD pathway kinase inhibitors perifosine and H89. Drug IC 50 values were computed using GraphPad with Sigmoidal dose-response algorithm.

    Techniques Used:



    Similar Products

    sigmoidal dose-response algorithm (as implemented in graphpad prism 7)  (GraphPad Software Inc)
    90
    GraphPad Software Inc sigmoidal dose-response algorithm (as implemented in graphpad prism 7)
    TNBC and non-TNBC cell cisplatin IC 50 values in the presence and absence of the BAD pathway kinase inhibitors perifosine and H89. Drug IC 50 values were computed using GraphPad with Sigmoidal <t> dose-response algorithm. </t>
    Sigmoidal Dose Response Algorithm (As Implemented In Graphpad Prism 7), supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sigmoidal+dose-response+algorithm+%28as+implemented+in+graphpad+prism+7%29/pmc06877530-209-20-25?v=GraphPad+Software+Inc
    Average 90 stars, based on 1 article reviews
    sigmoidal dose-response algorithm (as implemented in graphpad prism 7) - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    TNBC and non-TNBC cell cisplatin IC 50 values in the presence and absence of the BAD pathway kinase inhibitors perifosine and H89. Drug IC 50 values were computed using GraphPad with Sigmoidal dose-response algorithm.

    Journal: Scientific Reports

    Article Title: Expression of the BAD pathway is a marker of triple-negative status and poor outcome

    doi: 10.1038/s41598-019-53695-0

    Figure Lengend Snippet: TNBC and non-TNBC cell cisplatin IC 50 values in the presence and absence of the BAD pathway kinase inhibitors perifosine and H89. Drug IC 50 values were computed using GraphPad with Sigmoidal dose-response algorithm.

    Article Snippet: Comparing cisplatin IC 50 values in the presence and absence of perifosine or H89, which were calculated using the sigmoidal dose-response algorithm (as implemented in GraphPad Prism 7), indicated that the potentiation of cisplatin by a BAD protein kinase inhibitor was significant in the majority of TNBC cells but not in non-TNBC cells (Table ).

    Techniques: